Cenna生物科学公司为阿尔茨海默氏杆胺药物NubytideTM提供了27M阶段的SBIR赠款。 Cenna Biosciences secures $2.7M Phase II SBIR grant for Alzheimer's peptide drug, Nubytide™.

Cenna生物科学公司是一家设在La Jolla的生物制药公司,它从NIH和NIA获得了270万美元的第二阶段SBIR赠款,用于推进其旨在预防和治疗阿尔茨海默氏病的Peptide药物NubytideTM。 Cenna Biosciences, a biopharmaceutical company based in La Jolla, has secured a $2.7 million Phase II SBIR grant from the NIH and NIA to advance its peptide drug, Nubytide™, aimed at preventing and treating Alzheimer’s disease. 与目前的单克隆抗体治疗相比,这种创新疗法将更容易进行治疗,并可能减少副作用。 This innovative therapy promises easier administration and potentially fewer side effects compared to current monoclonal antibody treatments. 预计将于2025年初提交一项IND申报,并计划进一步投资以加快发展。 An IND filing is expected in early 2025, with plans for further investment to expedite development.